Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment
Dolutegravir durable with high rates of viral suppression in people who experienced virological failure with older integrase inhibitors
Efavirenz does not increase the risk of suicidal thoughts or depression in Ugandan adults
Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART
Transmitted drug resistance now less likely to harm HIV treatment options, US study finds
Potential interactions between ART and other medications present in over half of older HIV-positive people
Dolutegravir may cause birth defects, European Medicines Agency warns
High prevalence of menopausal symptoms in women living with HIV, but very few receive treatments for them
NHS England saved £10 million by switching to generic anti-HIV drugs in 2016
